PhaseBio Pharmaceuticals Total non-current assets

Total non-current assets of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Total non-current assets growth rates and interactive chart. The sum of all non-current or long-term assets.


Highlights and Quick Summary

  • Total non-current assets for the quarter ending September 29, 2021 was $12.5 Million (a 2.86% increase compared to previous quarter)
  • Year-over-year quarterly Total non-current assets increased by 22.3%
  • Annual Total non-current assets for 2020 was $10.2 Million (a 178.07% increase from previous year)
  • Annual Total non-current assets for 2019 was $3.67 Million (a 822.36% increase from previous year)
  • Annual Total non-current assets for 2018 was $398 Thousand (a 19.52% increase from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Total non-current assets of PhaseBio Pharmaceuticals

Most recent Total non-current assetsof PHAS including historical data for past 10 years.

Interactive Chart of Total non-current assets of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Total non-current assets for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $12.48 $12.14 $12.66
2020 $10.21 $8.26 $7.07 $4.32 $10.21
2019 $3.67 $2.83 $2.54 $2.31 $3.67
2018 $0.4 $2.52 $0.4
2017 $0.33

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.